Complex Karyotype and N-RAS Point Mutation in a Case of Acute Megakaryoblastic Leukemia (M7) Following a Myelodysplastic Syndrome

Fernandez, Teresa de Souza; Ornellas, Maria Helena; Carvalho, Luize Otero de; Maioli, Maria Christina Paixão; Lucena, Stella Beatriz Gonçalves de; Tabak, Daniel; Abdelhay, Eliana

doi:10.1016/s0165-4608(99)00153-3

Cited by 5 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[217][218][219][220][221][222][223][224][225][226][227] These point mutations can be induced by environmental mutagens. 224 Given the high level of mutations that have been detected at Ras, this pathway has always been considered a key target for therapeutic intervention.…”

Section: Roles Of the Ras/raf/mek/erk Pathway In Neoplasiamentioning

confidence: 99%

JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis

et al. 2004

View full text Add to dashboard Cite

Section: Roles Of the Ras/raf/mek/erk Pathway In Neoplasiamentioning

confidence: 99%

JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis

et al. 2004

View full text Add to dashboard Cite

“…Previous studies reported that AMGL includes not only idiopathic cases, but also the so‐called secondary AMGL, such as those that progress from MDS, CML, ET and CMF . In this study, six cases progressed from MDS, one case from CML, one case from ET and one case from CMF.…”

Section: Discussionmentioning

confidence: 59%

Clinicopathological features of acute megakaryoblastic leukaemia: Relationship between fibrosis and platelet‐derived growth factor

Niino

Tsuchiya

Tomonaga³

et al. 2013

Pathology International

View full text Add to dashboard Cite

Acute megakaryoblastic leukaemia (AMGL) is an uncommon disease with poor prognosis. Histopathologically, AMGL cases show variable degree of fibrosis and the presence of uniform blasts or mature dysplastic megakaryocytes. Here we examined 18 cases of AMGL, including idiopathic (n = 9) and secondary (n = 9) cases. Fourteen cases were males and four were females, ranging in age from 14 to 87 years (median, 58). All cases had anaemia, but leukocyte and platelet counts varied. Blast cells were detected in the peripheral blood of 14 cases. Fourteen of 16 cases showed chromosomal abnormalities. The median survival was 6 months (range, 1-48 months). Survival rates did not correlate with the severity of fibrosis, proportion of blast cells and cause of AMGL. Nine of the 11 cases examined immunohistochemically were positive for platelet-derived growth factor (PDGF)(-BB), especially megakaryoblasts and a few fibroblasts. The PDGF-positive cases showed various degrees of fibrosis, while the negative cases showed no evidence of fibrosis. Our results confirmed the poor prognosis of patients with AMGL, irrespective of the degrees of fibrosis, and demonstrated that PDGF could play an important role in the pathogenesis of marrow fibrosis.

show abstract

“…Adult AMKL is further divided into primary and secondary with both of them being very rare, and the latter is usually transformed by the progression of MDS [9][10][11][12] , chronic myeloid leukemia (CML) [13][14][15] , Essential thrombocythemia (ET) [16][17][18] and chronic idiopathic myelo brosis (CIMF) 15,19 . The patient had no previous history of CML.…”

Section: Discussionmentioning

confidence: 99%

First reported case of acute megakaryoblastic leukemia successfully treated with decitabine and venetoclax combined with imatinib

Shi¹

2021

Preprint

View full text Add to dashboard Cite

Acute megakaryocytic leukemia (AMKL) is a rare type of acute myeloid leukemia (AML), which is characterized by its effect on megakaryocytes in bone marrow. Despite standard doses of anthracycline plus cytarabine based regimen, AMKL is notorious for its poor prognosis. With the continuous development of targeted drugs, the choice of chemotherapy regimens for AML patients has been gradually enriched. However, as far as we known, there is little data with this regimen in AMKL with decitabine and Bcl-2 inhibitor combined with imatinib. Herein, we reported the first case of adult AMKL with BCR-ABL positive successfully treated with decitabine and venetoclax combined with imatinib.

show abstract

Complex Karyotype and N-RAS Point Mutation in a Case of Acute Megakaryoblastic Leukemia (M7) Following a Myelodysplastic Syndrome

Cited by 5 publications

References 17 publications

JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis

JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis

Clinicopathological features of acute megakaryoblastic leukaemia: Relationship between fibrosis and platelet‐derived growth factor

First reported case of acute megakaryoblastic leukemia successfully treated with decitabine and venetoclax combined with imatinib

Contact Info

Product

Resources

About